JOURNAL OF WORLD SCIENCE
https://jws.rivierapublishing.id/index.php/jws
Volume 2 No. 4 April 2023
P-ISSN: 2828-8726
E-ISSN: 2828-9307

ROLE OF ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR HEALTH CARE

Hafiz Khawar Hussain[1], Aftab Tariq[2], Ahmad Yousaf Gill[3]
DePaul University Jarvis College of Computing & Digital Media 243 S Wabash Ave, Chicago, United States
Department of Computer Science, American National University Salem Virginia, United States

hhussa14@depaul.edu[1], tariqa@students.an.edu[2], gilla@students.an.edu[3]

ABSTRACT
In the field of cardiovascular health, machine learning and artificial intelligence (AI) have become effective tools with potential applications ranging from disease detection and diagnosis to individualized treatment planning and decision making. The purpose of this study is to identify and analyze the role of AI in cardiovascular health care. The methodology of this review paper involved an extensive literature review of the existing research on the topic of AI in cardiovascular health care. Medical imaging is very important in the diagnosis and treatment of many diseases, but the interpretation of medical images is often time-consuming and subjective. Artificial intelligence (AI) algorithms, such as supervised and unsupervised learning, have been developed to assist in the analysis and interpretation of data from medical imaging. Convolutional neural networks (CNNs) and support vector machines (SVM) are the two most frequently used AI algorithms in medical image analysis. Artificial intelligence (AI) and machine learning in cardiovascular healthcare have great potential to improve patient outcomes and lower costs. However, there are still some hurdles that need to be overcome such as integration with clinical workflows, model validation and generalization, and privacy and security issues related to patient data. To overcome this, collaboration between doctors, researchers and industrial partners is needed. This technology has a bright and promising future with continuous investment in research and development.

Keyword: machine learning, ai, cardiovascular healthcare, disease detection, personalized treatment, risk stratification.

Corresponding Author: Hafiz Khawar Hussain
E-mail: hhussa14@depaul.edu

INTRODUCTION

In the entire world, cardiovascular diseases (CVDs) are a significant source of morbidity and mortality. The World Health Organisation (WHO) estimates that 17.9 million deaths worldwide each year are attributable to CVDs, or 31% of all fatalities (Bengio & LeCun, 2007). To improve patient outcomes and lower healthcare costs related to CVDs, early identification and effective treatment are essential (Silver et al., 2017). However, due to the complexity of the condition and the broad range in how patients exhibit and respond to treatment, diagnosing and managing CVDs can be difficult. Artificial intelligence (AI) and machine learning (ML) have become potent tools in healthcare, notably in the diagnosis and management of CVDs. Large volumes of clinical and imaging data may be processed by ML and AI algorithms to produce precise and individualised diagnosis, risk stratification, and therapy planning. An overview of the current state and potential applications of ML and AI in cardiovascular healthcare will be provided in this review article.

The importance of timely and accurate diagnosis of cardiovascular diseases coronary artery disease, heart failure, and stroke are among the conditions known as cardiovascular diseases (CVDs), which affect the heart and blood arteries. For lowering the risk of complications and improving patient outcomes, early CVD detection and diagnosis are essential (Berner et al., 1994). However, because of the disease's complexity and the broad range in how patients exhibit and respond to treatment, diagnosing CVDs can be difficult.

Historically, patient history, physical examination, lab testing, and imaging techniques have all been used to diagnose CVDs. Although these methods have been useful in many situations, they are frequently constrained by their subjectivity and the possibility of human mistake. Additionally, the interpretation of imaging tests such cardiac magnetic resonance imaging (MRI), echocardiography, and electrocardiography (ECG) can be challenging and time-consuming, necessitating specialized knowledge and skills. By offering precise and unbiased analysis of clinical and imaging data, ML and AI systems can get around these constraints. For instance, ML systems can be trained to recognize ECG signal patterns that signify heart diseases like atrial fibrillation or myocardial infarction. Similar to this, artificial intelligence (AI) algorithms can be used to analyse imaging images to find minute variations in heart structure and function that might be signs of early disease (Krittanawong et al., 2017).

ML and AI algorithms can aid in the identification of individuals who are at a high risk of developing CVDs in addition to enhancing the precision and speed of diagnosis. ML algorithms are able to categories individuals into different risk groups and forecast the likelihood that they will acquire CVDs by combining clinical and genetic data analysis (Deo, 2015). This can assist medical professionals in creating individualised treatment programs and closely monitoring patients for indications of illness development. Overall, the use of ML and AI to cardiovascular healthcare has the potential to increase diagnosis precision and timeliness, lower medical expenses, and enhance patient outcomes (Johnson et al., 2018). The incorporation of ML and AI algorithms into current clinical workflows, the validation and generalization of machine learning models across a range of patient populations, as well as the ethical and legal ramifications of AI-based diagnosis and treatment planning are some of the challenges and limitations that still need to be addressed.

Based on the background above, the purpose of this study was to identify and analyze the role of AI in cardiovascular health care. Research on the role of AI in cardiovascular health care has significant merit. First, research can help improve the effectiveness of cardiovascular care by identifying new, innovative, and efficient ways to diagnose, treat and prevent cardiovascular disease. Second, research can help reduce the cost of cardiovascular care by introducing more efficient and more cost-effective technologies. Third, research can raise awareness about the potential benefits and risks of using AI in cardiovascular care and help address the ethical and privacy issues associated with using this technology. Fourth, research can open new opportunities for the development of more sophisticated AI technologies that can adapt to the specific needs of patients. Thus, research on the role of AI in cardiovascular health care can make a significant contribution in improving the overall health and well-being of society.

METHOD

The methodology of this review paper involved an extensive literature review of the existing research on the topic of AI in cardiovascular health care. We identified and analyzed relevant peer-reviewed articles, research studies, and other sources of information related to the role of AI in cardiovascular health care. Once the relevant literature was identified, we conducted a thorough analysis to identify key trends, challenges, and opportunities in the field. Our goal was to provide a comprehensive overview of the current state of research on AI in cardiovascular health care and identify key areas for further investigation. To ensure the accuracy and reliability of our analysis, we used a rigorous methodology that included a systematic search of relevant databases, a detailed analysis of the research studies, and a critical evaluation of the findings. We also consulted with experts in the field to gain insights into the current state of research and best practices. In summary we would like to say the methodology of this review paper aimed to provide a comprehensive and objective overview of the role of AI in cardiovascular health care. Our analysis helped identify key opportunities and challenges in this field and provided valuable insights for researchers, clinicians, and policymakers.

RESULTS AND DISCUSSION

Medical Imaging and AI

The diagnosis and treatment of many medical disorders depend heavily on medical imaging. Medical imaging has improved in sophistication and accuracy as a result of technological advancements (Dilsizian & Siegel, 2018). However, because it depends on the knowledge and experience of the interpreter, medical image interpretation is a time-consuming and frequently subjective procedure. Artificial intelligence (AI) algorithms have been created recently to help in the analysis and interpretation of data from medical imaging (Kalinin et al., 2018). An overview of the various AI algorithms utilized in the analysis of medical imaging will be given in this section. Both supervised learning and unsupervised learning are common types of AI algorithms used in the analysis of medical imaging (Cavallari & Weitzel, 2015). Using labelled training data, the algorithm is taught to recognize particular patterns or characteristics in the images using supervised learning. The system can learn from a series of examples in the labelled training data, which also enables it to accurately categories fresh photos. Contrarily, using unsupervised learning, the system must independently find patterns or features using unlabeled training data (Sibbing et al., 2019).

Convolutional neural networks (CNNs) are one typical AI method utilized in the examination of medical imaging. CNNs are a subset of deep learning algorithms that are particularly beneficial for image analysis because they can find patterns in massive amounts of data. CNNs recognize features in the photos, such as edges or textures, using a number of layers of filters, and then utilize these features to categories the images. For instance, CNNs have been used to spot lung cancer on CT scans by locating tiny nodules that human radiologists could miss. Support vector machines (SVMs) are an additional AI algorithm that is frequently utilized in medical image analysis. Using their features, SVMs, a form of supervised learning algorithm, may categories images into several groups. SVMs operate by determining the best border between various categories in the data space. SVMs have been utilized for several imaging-related medical applications, including the detection of breast cancer in mammograms and the prognosis of Alzheimer's disease progression in MRI scans. Other AI algorithms utilized in medical imaging analysis, in addition to CNNs and SVMs, include random forests, decision trees, and k-nearest neighbors (Kitzmiller et al., 2016), (Pirmohamed et al., 2013). While k-nearest neighbors is an unsupervised learning technique that may detect comparable images based on their characteristics, random forests and decision trees are supervised learning algorithms that can categories images based on their properties (Syn et al., 2018).

Although AI algorithms have the potential to completely change the way that medical imaging analysis is done, they also have major drawbacks. The requirement for a significant volume of high-quality training data is one restriction (Li et al., 2020). It takes a sizable dataset of labelled photos that faithfully depict the disease or condition of interest to train an AI algorithm. It can be difficult to find such datasets, especially for rare diseases or ailments. The potential for data bias is still another drawback (Shah et al., 2015). The AI system may produce inaccurate predictions or fail to recognize specific scenarios if the training data is not representative of the population. The application of AI algorithms to the study of medical imaging also brings up moral and legal issues, such as patient confidentiality, data ownership, and accountability for wrong diagnoses. Medical image analysis could benefit from the accuracy and efficiency of AI algorithms (Shah, 2017). Support vector machines, convolutional neural networks, and other AI techniques can be used to find patterns in medical images and assist in the diagnosis and treatment of a variety of medical conditions (Shameer et al., 2018). However, there are also drawbacks to using AI algorithms for medical imaging analysis, such as the requirement for a substantial amount of high-quality training data and the possibility of bias in the data. As a result, ongoing research and development are required to guarantee the secure and efficient application of AI algorithms in the analysis of medical imaging.

Application of AI in cardiovascular Health Care

In order to effectively treat and manage cardiovascular diseases (CVDs), early detection and precise diagnosis are essential. CVDs are a primary cause of death and disability worldwide. Artificial intelligence (AI) and machine learning (ML) approaches have become effective tools for analyzing sizable patient data sets and discovering patterns in illness development and therapeutic response (Lee et al., 2017). We will examine the various uses of ML and AI in cardiovascular healthcare in this section, including the detection and diagnosis of CVDs, risk stratification and prediction of cardiovascular events, personalised treatment planning, and monitoring of cardiovascular health and disease progression (Krittanawong et al., 2018).

Cardiovascular Diseases: Detection and Diagnosis Using Machine Learning and AI

For the purpose of identifying and diagnosing CVDs, ML and AI algorithms have been applied to a variety of medical imaging investigations, such as cardiac MRI, CT scans, and echocardiography (Przewlocka-Kosmala et al., 2019). These algorithms can examine images and spot minor alterations in the structure and operation of the heart that might be signs of early illness. To detect individuals with diastolic dysfunction, a disorder in which the heart muscle stiffens and is unable to relax adequately between contractions, for instance, and ML algorithms can analyse echocardiogram images (Zellweger et al., 2018). Healthcare professionals can launch early therapies to stop the progression of disease via early recognition of diastolic dysfunction.

In addition to medical imaging, ML and AI algorithms have been used to detect and diagnose CVDs in other types of patient data, such as electrocardiograms (ECGs). For instance, using ECG data analysis, ML algorithms may spot patients who have arrhythmias, a disease in which the heart beats erratically. Healthcare professionals can start early therapies to stop the onset of more serious CVDs, like heart failure, by early detecting arrhythmias (Zellweger et al., 2014).

Prediction of Cardiovascular Events and Risk Stratification

Predictive models that can identify individuals who are at a high risk of developing CVDs or experiencing cardiovascular events, such as heart attacks or strokes, can be created using ML and AI algorithms. These algorithms may examine sizable patient data sets, including demographic, clinical, and genetic information, to find patterns in illness progression and potential risk factors for CVDs. In order to identify patients who are at a high risk of developing heart failure, a condition in which the heart is unable to properly pump blood, for instance, and ML algorithms can analyse patient data. Healthcare professionals can start early interventions to stop disease development and lower the risk of hospitalization and mortality via early identification of high-risk individuals.

Personalized Treatment Planning and Decision-making

Based on each patient's specific traits and stage of the disease, ML and AI algorithms can be utilized to create individualised treatment programs. To find patterns in illness development and therapeutic response, these algorithms may analyse enormous databases of patient data, including demographic, clinical, and genetic information. For individuals with hypertension, a condition in which the blood pressure is constantly raised, ML algorithms can examine patient data to determine the most efficient therapy. These algorithms can determine the best treatments and dosages for specific individuals by examining trends in disease progression and therapeutic response, lowering the risk of side effects and enhancing treatment outcomes (Khamis et al., 2017).

Monitoring of cardiovascular health and disease progression

Finally, AI and machine learning can be used to follow the development of diseases over time and monitor patients' cardiovascular health. These technologies are able to provide real-time insights into patient health and identify early warning signals of impending cardiovascular events by analyzing data from wearable, medical imaging, and electronic health records (van Rosendael et al., 2018). Machine learning algorithms, for instance, can be trained to analyse electrocardiogram (ECG) data and find anomalies that could point to a higher risk of heart attack or stroke. Similar to this, AI can be employed to examine data from medical imaging and spot changes in the composition or operation of the heart that might portend the beginning of cardiovascular illness. Machine learning and AI can assist in improving patient outcomes and lowering healthcare costs by avoiding expensive hospital stays and emergency interventions by monitoring patients in real-time and offering early warnings of potential health problems (van Rosendael et al., 2018).

By enhancing the precision and effectiveness of disease detection and diagnosis, forecasting cardiovascular events and risk, personalizing treatment planning and decision-making, and tracking patient health in real-time, machine learning and AI have the potential to completely transform the field of cardiovascular healthcare. Although there are still difficulties and restrictions to be resolved, the quick development of these technologies suggests that they will become more crucial to cardiovascular healthcare in the years to come (Al'Aref et al., 2019). We can work towards a future where cardiovascular illness is recognized and treated earlier, more efficiently, and with fewer consequences by utilizing the potential of machine learning and AI (Peng et al., 2016).

Challenges and Limitations

For machine learning and AI to be successfully implemented in cardiovascular healthcare, a number of issues and restrictions must be resolved (Zhou et al., 2011). We will go through some of the biggest obstacles to machine learning and artificial intelligence in cardiovascular healthcare in this part.

Integration with existing clinical workflows and electronic health records:

The integration of machine learning and AI with current clinical procedures and electronic health records (EHRs) is one of the biggest obstacles to its use in cardiovascular healthcare.

Electronic health records, or EHRs, are crucial for delivering prompt and efficient care because they contain information about a patient's medical history, diagnosis, medications, and other pertinent clinical data. However, the lack of standardization in EHRs makes it challenging to incorporate machine learning techniques into the current healthcare system. The adoption of new technology may also be hampered by healthcare practitioners' possible resistance to change (Balanescu et al., 2018).

Validation and generalization of machine learning models in diverse patient populations:

Validating and generalizing machine learning models across a range of patient groups is a significant obstacle to the application of AI and machine learning in cardiovascular healthcare. Large datasets are necessary for machine learning algorithms to train and improve their models. These statistics, however, frequently exhibit bias towards particular demographics, such as age, gender, or ethnicity. This may restrict how broadly the algorithms may be applied and produce erroneous predictions in some patient populations (Powles & Hodson, 2017). Additionally, over fitting in machine learning models might produce outcomes that are excessively hopeful.

Privacy and security concerns in handling patient data:

Large volumes of patient data are used by machine learning and AI algorithms to train and improve their models. However, handling patient data in this manner presents privacy and security issues. To avoid unauthorized access or data breaches, healthcare organizations must make sure that patient data is adequately de-identified and protected (Constantinides & Fitzmaurice, 2018). In order to preserve patient privacy, healthcare professionals must also make sure that they are adhering to laws like HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation).

Ethical and legal implications of AI-based diagnosis and treatment planning:

Algorithms that use machine learning and artificial intelligence (AI) can diagnose patients more quickly and with greater accuracy. However, there are a number of moral and legal issues with using these technology in healthcare. For instance, if these algorithms are being used to make life-or-death choices, there may be issues about their openness. Additionally, there can be issues with access to these technologies being equally distributed, especially for vulnerable patient populations. The liability of healthcare practitioners in the event of a negative incident or a malpractice claim may also be a source of concern. For machine learning and AI to be successfully implemented in cardiovascular healthcare, a number of issues and restrictions must be resolved. These difficulties include incorporating these tools into clinical workflows and electronic medical records as they currently stand, validating and generalizing machine learning models across a range of patient populations, ensuring the privacy and security of patient data, and dealing with the moral and legal ramifications of AI-based diagnosis and treatment. To overcome these obstacles and take use of the promise of machine learning and AI to enhance patient outcomes and quality of care, healthcare organizations and providers must collaborate (Laser et al., 2014).

CONCLUSION

In summary, artificial intelligence (AI) and machine learning have the potential to revolutionize cardiovascular healthcare in the years to come. The integration with current clinical workflows and electronic health records, validation, and generalization of machine learning models across a range of patient populations, and privacy and security issues when handling patient data are just a few of the obstacles that need to be overcome. However, the potential benefits are substantial. Further study is required in several areas before machine learning and AI can completely realize their potential in cardiovascular treatment. The creation of more precise and trustworthy predictive models, generalization of these models over a range of patient groups, and incorporation of machine learning and AI into current clinical procedures are a few of these. To guarantee that new technologies are created and applied in a responsible and ethical manner, there is also a need for collaboration between physicians, researchers, and industrial partners. This includes resolving the privacy and security issues related to handling patient data as well as making sure that all patients, regardless of socioeconomic situation, have access to this technology. Overall, machine learning and AI have a bright future in cardiovascular healthcare and hold enormous promise for raising patient outcomes and lowering costs. These technologies have the potential to completely alter how we detect, diagnose, and treat cardiovascular illnesses with continuous investment in research and development.

REFERENCES

Al'Aref, S. J., Anchouche, K., Singh, G., Slomka, P. J., Kolli, K. K., Kumar, A., Pandey, M., Maliakal, G., Van Rosendael, A. R., & Beecy, A. N. (2019). Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging. *European Heart Journal*, *40*(24), 1975–1986. https://doi.org/10.1093/eurheartj/ehy404

Balanescu, D. V., Monlezun, D. J., Teodora Donisan, M. D., David Boone, M. D., Frances Cervoni-Curet, M. D., Nicolas Palaskas, M. D., Juan Lopez-Mattei, M. D., Peter Kim, M. D., Cezar Iliescu, M. D., & Balanescu, S. M. (2018). A cancer paradox: machine-learning backed propensity-score analysis of coronary angiography findings in cardio-oncology. *Journal of Invasive Cardiology*, *31*(1).

Cavallari, L. H., & Weitzel, K. (2015). Pharmacogenomics in cardiology–genetics and drug response: 10 years of progress. *Future Cardiology*, *11*(3), 281–286.

Constantinides, P., & Fitzmaurice, D. A. (2018). Artificial intelligence in cardiology: applications, benefits and challenges. *Br J Cardiol*, *25*(3), 86–87. doi:10.5837/bjc.2018.024

Deo, R. C. (2015). Machine learning in medicine. *Circulation*, *132*(20), 1920–1930.

Dilsizian, M. E., & Siegel, E. L. (2018). Machine meets biology: a primer on artificial intelligence in cardiology and cardiac imaging. *Current Cardiology Reports*, *20*, 1–7.

Johnson, K. W., Torres Soto, J., Glicksberg, B. S., Shameer, K., Miotto, R., Ali, M., Ashley, E., & Dudley, J. T. (2018). Artificial intelligence in cardiology. *Journal of the American College of Cardiology*, *71*(23), 2668–2679.

Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., Najarian, K., & Athey, B. D. (2018). Deep learning in pharmacogenomics: from gene regulation to patient stratification. *Pharmacogenomics*, *19*(7), 629–650. https://doi.org/10.2217/pgs-2018-0008

Khamis, H., Zurakhov, G., Azar, V., Raz, A., Friedman, Z., & Adam, D. (2017). Automatic apical view classification of echocardiograms using a discriminative learning dictionary. *Medical Image Analysis*, *36*, 15–21. https://doi.org/10.1016/j.media.2016.10.007

Kitzmiller, J. P., Mikulik, E. B., Dauki, A. M., Murkherjee, C., & Luzum, J. A. (2016). Pharmacogenomics of statins: understanding susceptibility to adverse effects. *Pharmacogenomics and Personalized Medicine*, 97–106.

Krittanawong, C., Bomback, A. S., Baber, U., Bangalore, S., Messerli, F. H., & Wilson Tang, W. H. (2018). Future direction for using artificial intelligence to predict and manage hypertension. *Current Hypertension Reports*, *20*, 1–16.

Krittanawong, C., Zhang, H., Wang, Z., Aydar, M., & Kitai, T. (2017). Artificial intelligence in precision cardiovascular medicine. *Journal of the American College of Cardiology*, *69*(21), 2657–2664.

Laser, K. T., Horst, J.-P., Barth, P., Kelter-Klöpping, A., Haas, N. A., Burchert, W., Kececioglu, D., & Körperich, H. (2014). Knowledge-based reconstruction of right ventricular volumes using real-time three-dimensional echocardiographic as well as cardiac magnetic resonance images: comparison with a cardiac magnetic resonance standard. *Journal of the American Society of Echocardiography*, *27*(10), 1087–1097. https://doi.org/10.1016/j.echo.2014.05.008

Lee, K.-T., Hour, A.-L., Shia, B.-C., & Chu, P.-H. (2017). The application and future of big database studies in cardiology: a single-center experience. *Acta Cardiologica Sinica*, *33*(6), 581.

Li, Q., Wang, J., Tao, H., Zhou, Q., Chen, J., Fu, B., Qin, W., Li, D., Hou, J., & Chen, J. (2020). The prediction model of warfarin individual maintenance dose for patients undergoing heart valve replacement, based on the back propagation neural network. *Clinical Drug Investigation*, *40*, 41–53. https://doi.org/10.1007/s40261-019-00850-0

Peng, P., Lekadir, K., Gooya, A., Shao, L., Petersen, S. E., & Frangi, A. F. (2016). A review of heart chamber segmentation for structural and functional analysis using cardiac magnetic resonance imaging. *Magnetic Resonance Materials in Physics, Biology and Medicine*, *29*, 155–195. https://doi.org/10.1007/s10334-015-0521-4

Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., & Stafberg, C. (2013). A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med*, *369*, 2294–2303.

Powles, J., & Hodson, H. (2017). Google DeepMind and healthcare in an age of algorithms. *Health and Technology*, *7*(4), 351–367. https://doi.org/10.1007/s12553-017-0179-1

Przewlocka-Kosmala, M., Marwick, T. H., Dabrowski, A., & Kosmala, W. (2019). Contribution of cardiovascular reserve to prognostic categories of heart failure with preserved ejection fraction: a classification based on machine learning. *Journal of the American Society of Echocardiography*, *32*(5), 604–615. https://doi.org/10.1016/j.echo.2018.12.002

Shah, S. J. (2017). Precision medicine for heart failure with preserved ejection fraction: an overview. *Journal of Cardiovascular Translational Research*, *10*(3), 233–244. https://doi.org/10.1007/s12265-017-9756-y

Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015). Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation*, *131*(3), 269–279.

Shameer, K., Johnson, K. W., Glicksberg, B. S., Dudley, J. T., & Sengupta, P. P. (2018). Machine learning in cardiovascular medicine: are we there yet? *Heart*, *104*(14), 1156–1164.

Sibbing, D., Aradi, D., Alexopoulos, D., Ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., & Gross, L. (2019). Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. *JACC: Cardiovascular Interventions*, *12*(16), 1521–1537.

Silver, D., Schrittwieser, J., Simonyan, K., Antonoglou, I., Huang, A., Guez, A., Hubert, T., Baker, L., Lai, M., & Bolton, A. (2017). Mastering the game of go without human knowledge. *Nature*, *550*(7676), 354–359.

Syn, N. L., Wong, A. L.-A., Lee, S.-C., Teoh, H.-L., Yip, J. W. L., Seet, R., Yeo, W. T., Kristanto, W., Bee, P.-C., & Poon, L. M. (2018). Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. *BMC Medicine*, *16*(1), 1–10.

van Rosendael, A. R., Maliakal, G., Kolli, K. K., Beecy, A., Al'Aref, S. J., Dwivedi, A., Singh, G., Panday, M., Kumar, A., & Ma, X. (2018). Maximization of the usage of coronary CTA derived plaque information using a machine learning based algorithm to improve risk stratification; insights from the CONFIRM registry. *Journal of Cardiovascular Computed Tomography*, *12*(3), 204–209. https://doi.org/10.1016/j.jcct.2018.04.011

Zellweger, M. J., Brinkert, M., Bucher, U., Tsirkin, A., Ruff, P., & Pfisterer, M. E. (2014). A new memetic pattern based algorithm to diagnose/exclude coronary artery disease. *International Journal of Cardiology*, *174*(1), 184–186. https://doi.org/10.1016/j.ijcard.2014.03.184

Zellweger, M. J., Tsirkin, A., Vasilchenko, V., Failer, M., Dressel, A., Kleber, M. E., Ruff, P., & März, W. (2018). A new non-invasive diagnostic tool in coronary artery disease: artificial intelligence as an essential element of predictive, preventive, and personalized medicine. *EPMA Journal*, *9*, 235–247. https://doi.org/10.1007/s13167-018-0142-x

Zhou, J., Qu, F., Sang, X., Wang, X., & Nan, R. (2011). Acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized Chinese women: a randomized controlled trial. *Evidence-Based Complementary and Alternative Medicine*, *2011*.